Japan's Kyowa Hakko Posts Strong Profits for Fiscal Year 2007
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Kyowa Hakko Kogyo Co. said the fiscal year ended March 31 saw strong earnings compared to previous years. The Tokyo-based company also said fiscal year 2007 was the final year of a three-year, medium-term business plan and that the company exceeded plan targets "significantly" for sales and operating income
You may also be interested in...
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts
TOKYO - The size of the up-front payment that Amgen provided Kyowa Hakko Kogyo this week to gain development and commercialization rights to the Phase I humanized monoclonal antibody KW-0761 for most of the world - except Japan, Korea, China and Taiwan - indicates strong interest in the Japanese company's Potelligent technology, experts say